AnHeart Therapeutics
Professor Sai-Hong Ignatius Ou is currently the Health Science Clinical Professor of Medicine in the Department of Medicine, Division of Hematology-Oncology at the University of California Irvine School of Medicine. Dr. Ou received his MD and PhD degrees from the University of Texas Southwestern Medical School and completed an internship and residency in internal medicine at Duke University Medical Center. Dr. Ou completed his hematology-oncology fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Ou has served as an institutional review committee member for more than 10 years at the University of California Irvine School of Medicine and has been involved in mentoring hematology-oncology fellows and other young investigators globally.
Dr. Ou is one of the eight original phases 1 investigators of crizotinib, and is the senior and corresponding author of the US phase 1 dose escalation of alectinib in the US and participated in the clinical trials of lorlatinib. Dr. Ou has published close to 130 peer-reviewed articles including publications in the New England Journal of Medicine, The Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, and Cancer Discovery. Dr. Ou was on the scientific advisory board of TurningPoint Therapeutics which is developing the fourth-generation ALK/ROS1/NTRK inhibitor that can overcome solvent front mutations. His major research interests are in targeted therapy in lung cancer and other solid malignancies that harbors actionable driver mutations in particular receptor tyrosine kinase fusions and the strategies to overcome resistance to tyrosine kinase inhibitors. Dr. Ou serves on the editorial board of Annals of Oncology, Clinical Lung Cancer, and Translational Lung Cancer Research and has been an ad hoc reviewer for the New England Journal of Medicine, The Lancet, The Lancet Oncology, and Journal of Clinical Oncology among other journals. Dr. Ou is on the scientific committee for metastatic lung cancer at the American Society of Clinical Oncology annual meeting from 2016-2018.
This person is not in the org chart
This person is not in any offices
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.